Abera Bioscience AB (NGM:ABERA)
Sweden · Delayed Price · Currency is SEK 8.52
+0.52 (6.50%)
At close: Jun 15, 2026
Abera Bioscience AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | 11.83 | 11.85 | 14.63 | 2.52 | 1.79 | 1.18 |
| 11.83 | 11.85 | 14.63 | 2.52 | 1.79 | 1.18 | |
Revenue Growth (YoY) | -25.75% | -18.99% | 479.60% | 41.18% | 51.78% | 55.92% |
Gross Profit | 11.83 | 11.85 | 14.63 | 2.52 | 1.79 | 1.18 |
Selling, General & Admin | 27.92 | 22.12 | 15.72 | 19.35 | 21.19 | 10.34 |
Other Operating Expenses | 0.14 | 0.16 | 0.18 | 0.09 | 0.05 | 0.02 |
Operating Expenses | 28.28 | 22.47 | 15.97 | 19.45 | 21.24 | 10.35 |
Operating Income | -16.45 | -10.61 | -1.34 | -16.92 | -19.45 | -9.18 |
Interest Expense | -0 | - | -0 | - | - | -0 |
Interest & Investment Income | 0.15 | 0.13 | 0.02 | 0.08 | 0.01 | - |
Currency Exchange Gain (Loss) | 0.04 | 0.04 | 0.22 | 0.12 | 0.06 | 0.01 |
Other Non Operating Income (Expenses) | - | - | -0 | -0 | - | - |
Pretax Income | -16.26 | -10.45 | -1.1 | -16.72 | -19.38 | -9.17 |
Net Income | -16.26 | -10.45 | -1.1 | -16.72 | -19.38 | -9.17 |
Net Income to Common | -16.26 | -10.45 | -1.1 | -16.72 | -19.38 | -9.17 |
Shares Outstanding (Basic) | 20 | 17 | 16 | 13 | 12 | 10 |
Shares Outstanding (Diluted) | 20 | 17 | 16 | 13 | 12 | 10 |
Shares Change (YoY) | 33.52% | 5.59% | 18.42% | 13.66% | 14.64% | 45.39% |
EPS (Basic) | -0.79 | -0.63 | -0.07 | -1.26 | -1.66 | -0.90 |
EPS (Diluted) | -0.79 | -0.63 | -0.07 | -1.26 | -1.66 | -0.90 |
Free Cash Flow | -10.54 | -3.68 | -1.33 | -17.71 | -19.69 | -9.68 |
Free Cash Flow Per Share | -0.51 | -0.22 | -0.09 | -1.33 | -1.69 | -0.95 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -139.03% | -89.56% | -9.15% | -670.48% | -1088.19% | -779.01% |
Profit Margin | -137.46% | -88.20% | -7.52% | -662.44% | -1084.01% | -778.09% |
Free Cash Flow Margin | -89.08% | -31.09% | -9.09% | -701.70% | -1101.46% | -821.76% |
EBITDA | -16.24 | -10.42 | -1.28 | - | - | - |
EBITDA Margin | -137.24% | -87.95% | -8.73% | - | - | - |
D&A For EBITDA | 0.21 | 0.19 | 0.06 | - | - | - |
EBIT | -16.45 | -10.61 | -1.34 | -16.92 | -19.45 | -9.18 |
EBIT Margin | -139.03% | -89.56% | -9.15% | - | - | - |
Revenue as Reported | 11.87 | 11.89 | 14.85 | 2.65 | 1.85 | 1.19 |